Skip to main content

The small-cap sector dragged under the broad indices Friday, under pressure from falling names like

Spectrum Pharmaceuticals

(SPPI) - Get Spectrum Pharmaceuticals, Inc. Report


GPC Biotech

( GPCB).

Shares of the companies plummeted 28.5% and 35.9% respectively after a Food and Drug Administration advisory committee raised questions regarding their proposed prostate-cancer treatment, satraplatin, ahead of a July 24 meeting on the drug.


( PHRM), which has commercialization rights to the drug in Europe, Australia and elsewhere, fell 6.9% to $25.28.


( CYBS), a payment processor based in Mountain View, Calif., slid nearly 13% to $12.03 after forecasting third-quarter non-GAAP income of 6 cents a share -- 3 cents short of Thomson Financial's estimates. Second-quarter earnings were in line.


(ANET) - Get Arista Networks, Inc. Report

, which agreed to be bought by CyberSource in a stock-and-cash transaction last month, finished some 10% lower at $17.92.

Actions Semiconductor


TheStreet Recommends

lost 16.3% to $5.02 after reporting lower-than-expected income of $9.8 million, or 11 cents per American depositary share, in the second quarter -- nearly half of last year's EPS. West Virginia's

International Coal Group

( ICO) posted a second-quarter loss that, at 7 cents a share, was a nickel wider than anticipated. Shares tumbled 10.3% to $5.07.


Buckeye Technologies

(BKI) - Get Black Knight, Inc. Report

was lowered to reduce from neutral at UBS. The Memphis-based maker of cellulose-based specialty products shed $2.04, or 11.6%, to $15.51.

On the flip side, however,

Nucryst Pharmaceuticals

( NCST) saw an explosion in trading volume that recently sent shares up some 190% after the FDA approved its broad-spectrum antimicrobial-barrier topical cream. The product contains Nucryst's patented nanocrystalline silver technology. Shares were soaring $4.25 to $6.48.

Elsewhere in the health-care sector,

Progenics Pharmaceuticals

(PGNX) - Get Progenics Pharmaceuticals, Inc. Report

announced, jointly with


( WYE), positive preliminary early-phase results for a new oral formulation of constipation treatment methylnaltrexone. Progenics was up 12% to $23.96; Wyeth slipped 1%.


(OMCL) - Get Omnicell, Inc. Report

, a purveyor of management technology for use in health facilities, was 11.6% higher after edging past second-quarter profit estimates. And


( HIFN), a Los Gatos, Calif., semiconductor firm, swung to a profit of 2 cents a share vs. a 16-cent loss a year ago. Analysts had sought a break-even bottom line. Shares were leaping 18% to $7.47.

But, more broadly, the Russell 2000 sank 11.04 points, or 1.3%, to 840.81. The S&P SmallCap 600 gave back 1.2% to 439.84.

As originally published, this story contained an error. Please see

Corrections and Clarifications.